-
1.发明授权Metabolic pathway engineering to increase production of ascorbic acid intermediates 失效代谢途径工程增加抗坏血酸中间体的生产
公开(公告)号：US5032514A
公开(公告)日：1991-07-16
申请号：US229598
申请日：1988-08-08
CPC分类号： C12N9/0006 , C12P7/60
摘要： In recombinant microorganisms which were rendered capable of converting 2,5-diketo-D-gluconic acid (2,5-DKG) to 2-keto-L-gulonic acid (2-KLG) by transfer of genetic material, the secondary metabolites and metabolic pathways leading to the metabolic diversion of 2-KLG and 2,5-DKG were determined, and the diversion of 2-KLG to L-iodonic acid (IA) or of 2,5-DKG to 5-keto-D-gluconate (5-KDH) was blocked.
摘要翻译： 在通过遗传物质转移能够将2,5-二酮-D-葡糖酸（2,5-DKG）转化为2-酮-L-古洛糖酸（2-KLG）的重组微生物中，次级代谢物和 确定导致2-KLG和2,5-DKG代谢转移的代谢途径，并且将2-KLG转移到L-碘酸（IA）或2,5-DKG转化为5-酮-D-葡萄糖酸盐 （5-KDH）。
-
公开(公告)号：US5376544A
公开(公告)日：1994-12-27
申请号：US941414
申请日：1992-09-08
IPC分类号： C12N15/09 , C12N1/21 , C12N9/04 , C12N15/53 , C12N15/74 , C12P7/60 , C12R1/01 , C12R1/02 , C12R1/18
CPC分类号： C12N9/0006 , C12N15/74 , C12P7/60
摘要： Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
摘要翻译： 通过定点诱变制备2,5-二酮-D-葡糖酸还原酶A的突变体，A是用于产生2-酮-L-古洛糖酸的酶，抗坏血酸（维生素C）的前体。 这些突变体具有增加的催化活性，增加的表达水平和/或增强的温度稳定性。
-
公开(公告)号：US07256027B1
公开(公告)日：2007-08-14
申请号：US09332886
申请日：1999-06-15
CPC分类号： C12P7/60 , C12N9/0006
摘要： Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
摘要翻译： 通过定点诱变制备2,5-二酮-D-葡糖酸还原酶A的突变体，A是用于产生2-酮-L-古洛糖酸的酶，抗坏血酸（维生素C）的前体。 这些突变体具有增加的催化活性，增加的表达水平和/或增强的温度稳定性。
-
公开(公告)号：US5583025A
公开(公告)日：1996-12-10
申请号：US249377
申请日：1994-05-24
IPC分类号： C12N15/09 , C12N1/21 , C12N9/04 , C12N15/53 , C12N15/74 , C12P7/60 , C12R1/01 , C12R1/02 , C12R1/18
CPC分类号： C12N9/0006 , C12N15/74 , C12P7/60
摘要： Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
-
公开(公告)号：US5912161A
公开(公告)日：1999-06-15
申请号：US749337
申请日：1996-11-14
IPC分类号： C12N15/09 , C12N1/21 , C12N9/04 , C12N15/53 , C12N15/74 , C12P7/60 , C12R1/01 , C12R1/02 , C12R1/18 , C07H21/04
CPC分类号： C12N9/0006 , C12N15/74 , C12P7/60
摘要： Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
摘要翻译： 通过定点诱变制备2,5-二酮-D-葡糖酸还原酶A的突变体，A是用于产生2-酮-L-古洛糖酸的酶，抗坏血酸（维生素C）的前体。 这些突变体具有增加的催化活性，增加的表达水平和/或增强的温度稳定性。
-
公开(公告)号：US20080293121A1
公开(公告)日：2008-11-27
申请号：US12166128
申请日：2008-07-01
申请人： Robert A. Lazarus , Clark Qun Pan
发明人： Robert A. Lazarus , Clark Qun Pan
摘要： The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
摘要翻译： 本发明涉及具有增加的DNA-水解活性的人类DNA酶I的氨基酸序列变体。 本发明提供了编码这种多活性变体的核酸序列，从而使得能够以足以临床使用的量生产这些变体。 本发明还涉及人DNase I的多活性变体的药物组合物和治疗用途。
-
7.发明申请公开(公告)号：US20080195366A1
公开(公告)日：2008-08-14
申请号：US12057291
申请日：2008-03-27
IPC分类号： G06G7/60
CPC分类号： C07K14/4753 , C07K2299/00 , G16B15/00 , G16B20/00
摘要： The disclosure provides a crystal and crystal structure of the Hepatocyte Growth Factor Beta (HGF β) Chain, as well as use of the crystal structure in the design, identification, and selection of modulators of HGF or Met activity.
摘要翻译： 本公开提供了肝细胞生长因子β（HGFβ）链的晶体和晶体结构，以及在HGF或Met活性调节剂的设计，鉴定和选择中使用晶体结构。
-
公开(公告)号：US07084109B2
公开(公告)日：2006-08-01
申请号：US10202915
申请日：2002-07-25
CPC分类号： C07K7/08 , A61K38/00 , Y10S514/824
摘要： This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
-
公开(公告)号：US5880256A
公开(公告)日：1999-03-09
申请号：US399115
申请日：1995-03-03
申请人： Mark S. Dennis , Robert A. Lazarus
发明人： Mark S. Dennis , Robert A. Lazarus
IPC分类号： C12N15/09 , A61K38/00 , A61K38/43 , A61K38/48 , A61P7/02 , C07H21/04 , C07K14/81 , C12N1/21 , C12N9/99 , C12N15/15 , C12P21/02 , C12R1/19 , A61K38/55
CPC分类号： C07K14/8114 , A61K38/00 , Y10S514/822
摘要： A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.
摘要翻译： 提供能够抑制因子VIIa，因子XIa，血浆激肽释放酶或纤溶酶的强效丝氨酸蛋白酶抑制剂。 抑制剂提供在用于治疗其中指示因子VIIa，因子XIa，血浆激肽释放酶或纤溶酶的抑制的疾病的药物组合物中。
-
公开(公告)号：US5795954A
公开(公告)日：1998-08-18
申请号：US206310
申请日：1994-03-04
申请人： Robert A. Lazarus , Mark S. Dennis
发明人： Robert A. Lazarus , Mark S. Dennis
IPC分类号： C12N15/09 , A61K38/00 , A61K38/43 , A61K38/48 , A61P7/02 , C07H21/04 , C07K14/81 , C12N1/21 , C12N9/99 , C12N15/15 , C12P21/02 , C12R1/19 , A61K38/16 , A61K38/57
CPC分类号： C07K14/8114 , A61K38/00 , Y10S514/822
摘要： A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, and plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.
摘要翻译： 提供能够抑制因子VIIa，因子XIa，血浆激肽释放酶和纤溶酶的强效丝氨酸蛋白酶抑制剂。 抑制剂提供在用于治疗其中指示因子VIIa，因子XIa，血浆激肽释放酶或纤溶酶的抑制的疾病的药物组合物中。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.044 秒)
